



Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Hegi ME, Diserens A-C, Gorlia T, et al. *MGMT* gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;352:997-1003.



O	N	Number of patients at risk :						
223	266	215	136	79	31	12	1	— Not performed
257	307	271	182	89	49	17	3	— Performed



O	N	Number of patients at risk :							
310	367	302	195	106	49	18	2	— Unsucessfull	
170	206	184	123	62	31	11	2	— Sucessfull	

Legend for Supplementary Figure

Supplementary Figure 1. **Survival characteristics of patients for whom the *MGMT***

methylation status was assessed. The patients for whom the *MGMT* promoter

methylation status was determined is representative of the whole study population.

Overall survival was not different whether or not the MSP-test was performed **(A)**.

Likewise, patients had similar overall survival whether or not the test was interpretable

(B).